These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25989222)

  • 1. Assessing switchability for biosimilar products: modelling approaches applied to children's growth.
    Belleli R; Fisch R; Renard D; Woehling H; Gsteiger S
    Pharm Stat; 2015; 14(4):341-9. PubMed ID: 25989222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data.
    López-Siguero JP; Pfäffle R; Chanson P; Szalecki M; Höbel N; Zabransky M
    Drug Des Devel Ther; 2017; 11():1489-1495. PubMed ID: 28553079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial.
    Borrás Pérez V; López-Siguero JP; Martínez G; Corripio R; Fernández JM; Labarta JI; Ferrer M; Cabrinety N; Prieto P; Ramón-Krauel M; Bosch J; Espino R; Palla Garcia M; Rebollo FJ
    Adv Ther; 2015 Feb; 32(2):148-56. PubMed ID: 25667132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study.
    Iughetti L; Tornese G; Street ME; Napoli F; Giavoli C; Antoniazzi F; Stagi S; Luongo C; Azzolini S; Ragusa L; Bona G; Zecchino C; Aversa T; Persani L; Guazzarotti L; Zecchi E; Pietropoli A; Zucchini S
    Ital J Pediatr; 2016 Nov; 42(1):93. PubMed ID: 27809913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten years of clinical experience with biosimilar human growth hormone: a review of safety data.
    Borrás Pérez MV; Kriström B; Romer T; Walczak M; Höbel N; Zabransky M
    Drug Des Devel Ther; 2017; 11():1497-1503. PubMed ID: 28553080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R; Bidlingmaier M; Kreitschmann-Andermahr I; Land C; Partsch CJ; Schwab KO; Sommer H; Backeljauw P; Kanumakala S; Loche S; Zouater H; Strasburger CJ
    Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
    Romer T; Saenger P; Peter F; Walczak M; Le Bouc Y; Khan-Boluki J; Berghout A
    Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size calculations for the development of biosimilar products.
    Kang SH; Kim Y
    J Biopharm Stat; 2014; 24(6):1215-24. PubMed ID: 25032735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study.
    López-Siguero J; Borrás Pérez MV; Balser S; Khan-Boluki J
    Adv Ther; 2011 Oct; 28(10):879-93. PubMed ID: 21948492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study.
    Loche S; Kanumakala S; Backeljauw P; Schwab KO; Lechuga-Sancho AM; Esmael A; Urosevic D; Boldea A; Zabransky M
    Drug Des Devel Ther; 2024; 18():667-684. PubMed ID: 38454934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ten years experience with the first approved biosimilar recombinant human growth hormone drug in normal clinical practice].
    López-Siguero JP; Palla García M; Martínez Busto E; Rebollo FJ; Pombo M
    An Pediatr (Engl Ed); 2018 Apr; 88(4):209-215. PubMed ID: 28668339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten years of biosimilar recombinant human growth hormone in Europe.
    Saenger P
    Drug Des Devel Ther; 2017; 11():1505-1507. PubMed ID: 28553081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between growth response to growth hormone and baseline body composition of children with growth hormone deficiency.
    Esen I; Demirel F; Tepe D; Kara O; Koc N
    Growth Horm IGF Res; 2013 Oct; 23(5):196-9. PubMed ID: 23890535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional consistency and sample size considerations in a multiregional equivalence trial.
    Wu SC; Xu JF; Zhang XJ; Li ZW; He J
    Pharm Stat; 2020 Nov; 19(6):897-908. PubMed ID: 32716135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis.
    Stanhope R; Sörgel F; Gravel P; Pannatier Schuetz YB; Zabransky M; Muenzberg M
    J Clin Pharmacol; 2010 Nov; 50(11):1339-48. PubMed ID: 20173088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of recombinant human growth hormone for 1 year on body composition and muscle strength in children on long-term steroid therapy: randomized controlled, delayed-start study.
    Simon D; Alberti C; Alison M; Le Henaff L; Chevenne D; Boizeau P; Canal A; Ollivier G; Decostre V; Jacqz-Aigrain E; Carel JC; Czernichow P; Hogrel JY
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2746-54. PubMed ID: 23626006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.
    Iughetti L; Antoniazzi F; Giavoli C; Bona G; Aversa T; Greggio NA; Guazzarotti L; Minelli R; Perrone L; Persani L; Pozzobon G; Ragusa L; Stagi S; Tornese G; Zecchino C; Gallinari P; Zouater H; Fedeli P; Zucchini S
    J Endocrinol Invest; 2021 Mar; 44(3):493-503. PubMed ID: 32557273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The model of height prognosis in children with growth hormone deficiency].
    Kostecka L; Wasikowa R; Noczyńska A; Filipowski H
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):113-7. PubMed ID: 15504314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from originator recombinant growth hormone (Genotropin™) to biosimilar (CRISCY™): Results from a 6-month, multicentric, non-inferiority, extension trial.
    Czepielewski MA; Garret Q; Vencio SAC; Rassi N; Faria MS; Senn CCP; Bronstein MD; Cerqueira MJAG; Neves ACL; Spinola-Castro AM; Cunha MPR; Leite NR; Wassermann GE; Alegria MC; Toffoletto O; Afiune J; Baradelli R; Rodrigues DG; Scharf M
    Growth Horm IGF Res; 2021 Feb; 56():101372. PubMed ID: 33260063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.